money moves

Houston fintech unicorn raises $300M in series C

Last year, HighRadius became Houston's first unicorn — a privately held startup valued at over $1 billion. Now, the fintech company has raised more funds. Image via HighRadius.com

Houston's first "unicorn," fintech company HighRadius, is growing up fast.

On March 30, HighRadius, a software-as-a-service (SaaS) business, reported it raised a $300 million Series C round of funding that values the company at $3.1 billion. D1 Capital Partners and Tiger Global Management led the round, with participation from existing investors ICONIQ Growth and Susquehanna Growth Equity. Also contributing to the round were four high-profile entrepreneurs:

  • Frank Slootman, chairman and CEO of Snowflake, a cloud-computing company based in San Mateo, California. Both D1 Capital and Tiger Global invested in Snowflake, which went public in September.
  • Michael Scarpelli, chief financial officer of Snowflake.
  • Tooey Courtemanche, CEO of Carpinteria, California-based Procore Technologies, which produces software for management of construction projects. D1 Capital and Tiger Global are investors in Procore.
  • Howie Liu, co-founder and CEO of Airtable, a cloud-based collaboration platform based in San Francisco. D1 Capital is among Airtable's investors.

In a news release, HighRadius says it will spend the money to fuel product development and expand its global reach.

The $300 million funding round comes nearly 15 months after HighRadius announced it raised $125 million in a Series B round that catapulted it to unicorn status. In the fundraising world, a unicorn refers to a startup valued at $1 billion or more.

HighRadius, based in West Houston, was founded in 2006. It employs more than 1,000 people around the world. The HighRadius website listed 16 job openings as of March 30, with 10 of them in Houston.

HighRadius' AI-powered SaaS offering streamlines accounts-receivable and cash-management processes. For instance, HighRadius' Cash Application software relies on AI to comb through documents like emails and invoices to automatically match incoming payments with customer accounts. The company has over 600 customers, including more than 200 of the Forbes Global 2000.

"Our goal has always been to build a long-lasting business that outlasts all of us," Sashi Narahari, founder and CEO of HighRadius, says in the news release. "I look forward to working with [our] high-quality, long-term investors, who share a common vision of transforming the office of the CFO using a combination of artificial intelligence built on top of connected-finance workspaces and embedded analytics."

In the news release, Daniel Sundheim, founder of New York City-based D1 Capital, says CFOs and their teams have historically relied on antiquated methods to handle accounts receivable and cash management.

"HighRadius is in the opening innings of defining the next big software market for the office of the CFO," John Curtius, a partner at New York City-based Tiger Global, says in the news release. "HighRadius bears all of the signs of being a category-defining business for order-to-cash automation."

Trending News

Building Houston

 
 

Dr. Peter Hotez and Dr. Maria Elena Bottazzi have been recognized by Fast Company for their leadership in developing low-cost COVID vaccine. Photo courtesy of Texas Children's

This week, Fast Company announced its 14th annual list of Most Creative People in Business — and two notable Houstonians made the cut.

Dr. Peter Hotez and his fellow dean of the National School of Tropical Medicine at Baylor College of Medicine, Dr. Maria Elena Bottazzi, were named among the list for “open sourcing a COVID-19 Vaccine for the rest of the world.” The list, which recognizes individuals making a cultural impact via bold achievements in their field, is made up of influential leaders in business.

Hotez and Bottazzi are also co-directors for the Texas Children's Hospital's Center for Vaccine Development -one of the most cutting-edge vaccine development centers in the world. For the past two decades it has acquired an international reputation as a non-profit Product Development Partnership (PDP), advancing vaccines for poverty-related neglected tropical diseases (NTDs) and emerging infectious diseases of pandemic importance. One of their most notable achievements is the development of a vaccine technology leading to CORBEVAX, a traditional, recombinant protein-based COVID-19 vaccine.

"It's an honor to be recognized not only for our team's scientific efforts to develop and test low cost-effective vaccines for global health, but also for innovation in sustainable financing that goes beyond the traditional pharma business model," says Hotez in a statement.

The technology was created and engineered by Texas Children's Center for Vaccine Development specifically to combat the worldwide problem of vaccine access and availability. Biological E Limited (BE) developed, produced and tested CORBEVAX in India where over 60 million children have been vaccinated so far.

Earlier this year, the doctors were nominated for the 2022 Nobel Peace Prize for their research and vaccine development of the vaccine. Its low cost, ease of production and distribution, safety, and acceptance make it well suited for addressing global vaccine inequity.

"We appreciate the recognition of our efforts to begin the long road to 'decolonize' the vaccine development ecosystem and make it more equitable. We hope that CORBEVAX becomes one of a pipeline of new vaccines developed against many neglected and emerging infections that adversely affect global public health," says Bottazzi in the news release from Texas Children's.

Fast Company editors and writers research candidates for the list throughout the year, scouting every business sector, including technology, medicine, engineering, marketing, entertainment, design, and social good. You can see the complete list here

.

Trending News